Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 30;13(5):805.
doi: 10.3390/v13050805.

To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity

Felicia Schlotthauer  1   2 , Joey McGregor  1   2 , Heidi E Drummer  1   2   3
Affiliations
Review

To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity

Felicia Schlotthauer et al. Viruses. .

Abstract

Direct-acting antiviral agents have proven highly effective at treating existing hepatitis C infections but despite their availability most countries will not reach the World Health Organization targets for elimination of HCV by 2030. A prophylactic vaccine remains a high priority. Whilst early vaccines focused largely on generating T cell immunity, attention is now aimed at vaccines that generate humoral immunity, either alone or in combination with T cell-based vaccines. High-resolution structures of hepatitis C viral glycoproteins and their interaction with monoclonal antibodies isolated from both cleared and chronically infected people, together with advances in vaccine technologies, provide new avenues for vaccine development.

Keywords: glycoprotein E2; humoral immunity; vaccine development.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The antigenic organization of HCV glycoprotein E2 (PDB: 6MEJ) [25]. The front face of E2 (A) shows the location of domain E/epitope I (magenta), domain D/epitope II (cyan), domain B/AR3 (cyan/green), and domain C (orange). HVR2 and igVR/VR3 are shown in red. A 180° rotation of E2 (B) shows the location of HVR2 and the igVR/VR3 in red and regions contributing to non-NAb epitopes AR1 and domain A are shown in yellow. Glycans are depicted as spheres. (C) Schematic representation of the organization of the E2 ectodomain with locations of HVR1, HVR2 and igVR/VR3 (red), linear antigenic domains E (magenta) and D (cyan) and the CD81 binding loop (green).
See this image and copyright information in PMC

References

    1. Klein M.B. Hepatitis C virus elimination: Time for disruptive innovation. J. Int. AIDS Soc. 2019;22:e25360. doi: 10.1002/jia2.25360. - DOI - PMC - PubMed
    1. Scott N., Wilson D.P., Thompson A.J., Barnes E., El-Sayed M., Benzaken A.S., Drummer H.E., Hellard M.E. The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. BMC Med. 2019;17:175. doi: 10.1186/s12916-019-1411-9. - DOI - PMC - PubMed
    1. Alter M.J., Margolis H.S., Krawczynski K., Judson F.N., Mares A., Alexander W., Hu P.Y., Miller J.K., Gerber M.A., Sampliner R.E., et al. The Natural History of Community-Acquired Hepatitis C in the United States. N. Engl. J. Med. 1992;327:1899–1905. doi: 10.1056/NEJM199212313272702. - DOI - PubMed
    1. Smith D.B., Bukh J., Kuiken C.L., Muerhoff A.S., Rice C.M., Stapleton J.T., Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology. 2014;59:318–327. doi: 10.1002/hep.26744. - DOI - PMC - PubMed
    1. Borgia S.M., Hedskog C., Parhy B., Hyland R.H., Stamm L.M., Brainard D.M., Subramanian M.G., McHutchison J.G., Mo H., Svarovskaia E., et al. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. J. Infect. Dis. 2018;218:1722–1729. doi: 10.1093/infdis/jiy401. - DOI - PubMed

Publication types

MeSH terms